PGEN at a glance
PRECIGEN, INC. (PGEN, SEC CIK 1356090) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as September 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PRECIGEN, INC. (PGEN) reported revenue of $9.7 million (up 146.7% from FY2024) and a net loss of $250.6 million. Diluted EPS was -$1.37.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding PRECIGEN, INC. (PGEN) shares worth $334.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by KINDLER JEFFREY B on August 26, 2026 of 185,000 shares at $7.44 per share.
- In the last 90 days, PGEN insiders reported 1 open-market purchase ($25K) and 7 open-market sales ($3.4M) on Form 4, a net sale of $3.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $9.7M
- +146.7% vs prior year
- Insiders · 90 days
- 1 buy · 7 sells
- Net −$3.4M
- 13F holders
- 26 funds
- $334.7M · +3 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $54.978M vs $856K YoY, up $54.122M, driven by Papzimeos product revenue $53.262M
- Operating margin 41.2% vs negative 3,711.2% YoY; net income $20.071M vs $26.642M loss
- Best-performing line: Papzimeos, $53.1M Q2 sales; Exemplar service revenue $1.716M
- R&D expense $7.282M, down 36.6% YoY; SG&A $22.249M, up 37.9% on commercialization
- Gross margins expected to stabilize between high 80 percentages and low 90 percentages after pre-launch inventory sales
Risk Factors
- No material risk-factor changes disclosed; filing refers readers to Annual Report risks
- Insider-trading governance risk: CEO trading arrangement modified June 30, 2026
- Potential market overhang: remaining 130,424 shares eligible for CEO sales
- Securities-law compliance exposure: future Rule 10b5-1 transactions require Section 16 disclosure
AI summary of the PGEN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 contains Precigen’s financial results for the quarter ended June 30, 2026
- August 4, 2026 press release provides the substantive earnings details
Item EX-99.1: Item EX-99.1
- PAPZIMEOS revenue reached $53.1 million in Q2, more than doubling from the prior quarter and driving quarterly net income of $20.1 million
- Total revenue rose to $55.0 million from $0.9 million, while operating income reached $22.6 million versus a $31.8 million loss
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved 7 million additional shares under Precigen’s 2023 Omnibus Incentive Plan
- Expanded equity capacity supports future employee and executive compensation
Item 5.07: Submission of Matters to a Vote of Security Holders
- All nine director nominees elected for one-year terms, preserving board continuity
- Vinita Gupta faced strongest opposition, with 57,856,824 votes against
Item 2.02: Results of Operations and Financial Condition
- Precigen reported financial results for the quarter ended March 31, 2026
- Detailed results and management commentary appear in Exhibit 99.1 press release
AI summaries of PGEN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PGEN
Don't miss the next PGEN filing
- Alerts as it files. A push when PGEN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PGEN, by share count.
- Ask anything. An AI agent that reads every PGEN filing and answers with sources.
PGEN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Thomasian Harry Jr. | M | Sep 23, 2026 | 10,744 | - |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 1 | - |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 2 | - |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 42,918 | - |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 42,918 | $2.33 |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 10,744 | $4.72 |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 1 | $1.21 |
| Thomasian Harry Jr. | M | Sep 23, 2026 | 2 | $0.96 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $3.9M | $9.7M |
| Operating Income | -$99.8M | -$135.0M | -$110.5M |
| Net Income | -$95.9M | -$126.2M | -$250.6M |
| Op. Margin | - | -3440.2% | -1141.1% |
| Net Margin | - | -3216.2% | -2588.2% |
| Balance Sheet | |||
| Total Assets | - | $145.3M | $155.5M |
| Equity | - | $38.5M | $20.9M |
| ROE | - | -327.8% | -1198.6% |
| Per Share | |||
| EPS | - | $-0.47 | $-1.37 |
| Cash Flow | |||
| Operating CF | -$66.9M | -$68.2M | -$87.8M |
| CapEx | $1.5M | $8.6M | $2.0M |
Source: XBRL data in PRECIGEN, INC. (PGEN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PGEN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $334.7M |
| Q1 2026 | 23 | $209.2M |
| Q4 2025 | 20 | $236.6M |
| Q3 2025 | 23 | $130.5M |
| Q2 2025 | 23 | $44.3M |
| Q1 2025 | 22 | $26.1M |
| Q4 2024 | 17 | $16.9M |
| Q3 2024 | 13 | $7.6M |
- BlackRock+1.92M (+13%)
- State Street Corp+1.11M (+10%)
- Morgan Stanley+1.06M (+44%)
- Vanguard Capital Management LLC+757.2K (+11%)
- FMR LLC (Fidelity)+571.6K (+29%)
- Citadel Advisors LLC−1.88M (-70%)
- Franklin Resources−1.61M (-61%)
- AQR Capital Management−39.4K (-21%)
- JPMorgan Chase & Co−24.0K (-3%)
- Renaissance Technologies LLC+605.3K
- U.S. Bancorp+100.0K
- Allstate+15.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 167 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PGEN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 4 | May 27, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PGEN SEC filings: frequently asked questions
Are PGEN insiders buying or selling?
In the last 90 days, PRECIGEN, INC. (PGEN) officers, directors and 10% owners reported 1 open-market purchase worth $24,662 by 1 insider and 7 open-market sales worth $3.4 million by 4 insiders on Form 4, a net sale of $3.4 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PGEN stock?
As of June 30, 2026, the largest PRECIGEN, INC. (PGEN) holders among the 13F filers tracked by SignalX were BlackRock ($97.7 million), State Street Corp ($68.4 million), Vanguard Capital Management LLC ($45.1 million), Morgan Stanley ($19.8 million), Goldman Sachs Group ($19.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PGEN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PRECIGEN, INC. (PGEN) reported revenue of $9.7 million (up 146.7% from FY2024) and a net loss of $250.6 million. Diluted EPS was -$1.37. The figures come from the XBRL data in the 10-K.
What did PGEN report in its latest 8-K?
PRECIGEN, INC. (PGEN) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.1 contains Precigen’s financial results for the quarter ended June 30, 2026.
What are the latest PGEN SEC filings?
PRECIGEN, INC. (PGEN) filed its latest 10-K annual report on March 25, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on September 24, 2026.
What is PGEN's SEC CIK number?
PRECIGEN, INC. (PGEN)'s SEC Central Index Key (CIK) is 1356090. EDGAR lists every PGEN filing under that number.
Ask anything about PGEN
The research agent reads PGEN's filings, financials, insider trades and 13F holders, then answers with sources.